Bempedoic acid - Esperion Therapeutics

Drug Profile

Bempedoic acid - Esperion Therapeutics

Alternative Names: ESP-55016; ETC-1002

Latest Information Update: 17 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Esperion Therapeutics
  • Class Antihyperlipidaemics; Antihypertensives; Dicarboxylic acids; Fatty acids; Small molecules
  • Mechanism of Action ATP citrate (pro S) lyase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hypercholesterolaemia
  • Phase II Dyslipidaemias; Hypertension

Most Recent Events

  • 07 Mar 2018 Positive top-line efficacy and adverse events data from the CLEAR Tranquility phase III trial in Hypercholesterolaemia released by Esperion Therapeutics
  • 23 Feb 2018 9233924- Info already covered
  • 19 Feb 2018 Esperion Therapeutics completes a phase II trial for Hypercholesterolaemia (Adjunctive treatment) in USA (PO) (NCT03193047)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top